<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Act</title>
	<atom:link href="http://www.tapanray.in/tag/act/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>No Compromise: India Protects Patents Act in High-Stakes UK Trade Pact</title>
		<link>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact</link>
		<comments>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/#comments</comments>
		<pubDate>Wed, 30 Jul 2025 06:47:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2025]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[data exclusivity]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[no compromise]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10948</guid>
		<description><![CDATA[India, the &#8220;pharmacy of the world,&#8221; has long been a lifeline for millions, churning out affordable generic medicines that make healthcare accessible across the Global South. With over $25 billion generic drug industry exporting half its production, India’s commitment to &#8230; <a href="http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exploiting India&#8217;s Weakness For Monopolistic Commercial Gain?</title>
		<link>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exploiting-indias-weakness-for-monopolistic-commercial-gain</link>
		<comments>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/#comments</comments>
		<pubDate>Mon, 08 May 2023 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10776</guid>
		<description><![CDATA[Public access to healthcare in India is a complex issue with several challenges. While India has been making progress over the years in improving healthcare access and reducing the burden of disease, there are still significant disparities in healthcare access &#8230; <a href="http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unfettered ‘Access To Drug Innovation’ &#8211; An Oxymoron?</title>
		<link>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unfettered-access-to-drug-innovation-an-oxymoron</link>
		<comments>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/#comments</comments>
		<pubDate>Mon, 06 Sep 2021 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[customer. consumer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[off-patent]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[property< India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[undermining]]></category>
		<category><![CDATA[unfettered]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10582</guid>
		<description><![CDATA[The mass paranoia, as it were, over Covid pandemic has now started fading with drug regulators’ ‘emergency approval’ of several Covid -19 vaccines, and its free of cost access to all, generally in most countries. As the endgame of the pandemic, &#8230; <a href="http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Rare Strategic Acrobatic Feat in Covid Time</title>
		<link>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-rare-strategic-acrobatic-feat-in-covid-time</link>
		<comments>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/#comments</comments>
		<pubDate>Mon, 21 Dec 2020 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[acrobatic]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Alexion]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[comorbidity]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[feat]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infected patients]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[misdiagnosis]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[National Policy on rare diseases 2020]]></category>
		<category><![CDATA[new Coronavirus]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10376</guid>
		<description><![CDATA[‘Keep nose to the grindstone while lifting eyes to the hills.’ Quite a while ago, all-time global management guru – Peter Drucker used this essential acrobatic feat as an example, for the business strategists. This illustration signifies the criticality of harmonizing decisions &#8230; <a href="http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Opioid Crisis: A Looming Threat To India?</title>
		<link>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=opioid-crisis-a-looming-threat-to-india</link>
		<comments>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/#comments</comments>
		<pubDate>Mon, 16 Sep 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[flip side]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[narcotics]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Opioid]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[tryst]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9712</guid>
		<description><![CDATA[A serious, but a typical health crisis that has shaken America, is now, apparently, in search of its prey in India – a soft target to ignite a raging fire of misuse or abuse of prescription drugs of addictive in &#8230; <a href="http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OTC Drugs in India: ‘Where Art Thou?’</title>
		<link>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=otc-drugs-in-india-where-art-thou</link>
		<comments>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/#comments</comments>
		<pubDate>Mon, 02 Sep 2019 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advertisement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[classification]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[juggernaut]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[non-prescription]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[rule]]></category>
		<category><![CDATA[schedule K]]></category>
		<category><![CDATA[self-medication]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US_FDA]]></category>
		<category><![CDATA[Where Art Thou]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9692</guid>
		<description><![CDATA[It is now a widely accepted fact that responsible self-medication plays an important role in health care, facilitating greater access to medicines and reducing overall health care cost. With continued improvement in people&#8217;s education, general knowledge and socioeconomic conditions, self-medication has &#8230; <a href="http://www.tapanray.in/otc-drugs-in-india-where-art-thou/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Access To Comprehensive Healthcare Merits Multipronged Approach</title>
		<link>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=access-to-comprehensive-healthcare-merits-multipronged-approach</link>
		<comments>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/#comments</comments>
		<pubDate>Mon, 10 Dec 2018 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[band-aid]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[comprehensive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Gordian]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[knot]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[multi-pronged]]></category>
		<category><![CDATA[multifactorial]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9296</guid>
		<description><![CDATA[Since the turn of the new millennium, several high profile and flagship health schemes are being announced in India by the Union successive governments. Some of the important ones will include the National Health Mission, Rashtriya Swasthya Bima Yojana (RSBY) - a Health &#8230; <a href="http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making &#8216;National Policy For Rare Diseases&#8217; More Meaningful With &#8216;Orphan Drugs Act&#8217;</title>
		<link>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act</link>
		<comments>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/#comments</comments>
		<pubDate>Mon, 03 Jul 2017 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[CSTR]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[highlights]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[ODA]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8305</guid>
		<description><![CDATA[In November 2016, while hearing a related case, the Delhi High Court reportedly directed the Union Government to finalize and implement a policy on rare diseases, with a provision for free treatment with the expensive medications, as will be required by &#8230; <a href="http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dwindling Drug Innovation: Declining Image: Unchanged Business And Advocacy Models</title>
		<link>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models</link>
		<comments>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/#comments</comments>
		<pubDate>Mon, 20 Feb 2017 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Dwinding]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbows]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8099</guid>
		<description><![CDATA[A report of ‘The United States International Trade Commission (USITC)’ released on December 22, 2014 suggested, if tariffs and investment restrictions were fully eliminated, and standards of IP protection were made comparable to the U.S and Western European levels, American &#8230; <a href="http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mental Health Problem: A Growing Concern In The Healthcare Space Of India</title>
		<link>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india</link>
		<comments>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/#comments</comments>
		<pubDate>Mon, 16 Jan 2017 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[anxiety]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[dementia]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[Development Goals]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illness]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lok]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Rajya]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sabha]]></category>
		<category><![CDATA[SDG]]></category>
		<category><![CDATA[series]]></category>
		<category><![CDATA[stigma]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8049</guid>
		<description><![CDATA[A thud! Something fell from high above! In no time, a bright young life of just a 32-year-old highly accomplished professional &#8211; a widely admired soul, vanished in the thin year, for good, mostly unnoticed in the quiet neighborhood, initially. &#8230; <a href="http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
